COMMUNIQUÉS West-GlobeNewswire

PLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results

23/03/2018 - 11:50

HOUSTON, March 23, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP ) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 [...]

Shire plc : District Court Issues Ruling Finding Adderall XR® Patents Infringed

23/03/2018 - 10:15

District Court Issues Ruling Finding Adderall XR® Patents Infringed Cambridge, Mass., USA - March 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that its subsidiary, Shire Development LLC, welcomes yesterday's [...]

Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering

23/03/2018 - 07:15

TUCSON, Ariz., March 23, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (“Accelerate Diagnostics”) (NASDAQ: AXDX ) today announced the pricing of $150.0 million aggregate principal amount of 2.50% convertible [...]

Ozempic® approved in Japan for the treatment of type 2 diabetes

23/03/2018 - 07:13

Bagsværd, Denmark, 23 March 2018 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic ® (semaglutide), a new once-weekly analogue of human glucagon-like peptide-1 [...]

UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT BLUEPOINT BRUSSELS

23/03/2018 - 07:01

*** Unofficial English translation - For convenience purposes only *** UCB SA/NV - Public Limited Liability Company Allée de la Recherche 60, 1070 Brussels Enterprise nr. 0403.053.608 (RLE Brussels) (" UCB SA/NV " or [...]

UCB: CONVOCATION À L'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES QUI SE TIENDRA À BLUEPOINT BRUSSELS

23/03/2018 - 07:01

UCB - société anonyme Allée de la Recherche 60, 1070 Bruxelles n° d'entreprise 0403.053.608 (RPM Bruxelles) (« UCB SA » ou la « Société ») Convocation à l'Assemblée Générale des actionnaires qui se tiendra à BLUEPOINT [...]

INNATE PHARMA : Expansion of mCRC cohort in Phase I trial evaluating monalizumab with Imfinzi

23/03/2018 - 07:01

Partner MedImmune expands colorectal cancer patient cohort in ongoing PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI ® (DURVALUMAB) Additional expansion cohorts to explore the safety and efficacy of [...]

INNATE PHARMA : Extension de cohorte dans la Phase I évaluant monalizumab et Imfinzi dans le cancer colorectal

23/03/2018 - 07:01

MedImmune Étend l'essai de phase I en cours Évaluant MONALIZUMAB en combinaison avec Imfinzi ® (DURVALUMAB) et inclut de nouvelles cohortes de patients atteints d'un cancer colorectal Les cohortes additionnelles [...]

Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan

23/03/2018 - 02:30

CRANBURY, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the oral small molecule pharmacological [...]

Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit

23/03/2018 - 00:45

SYDNEY, Australia, March 22, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep” or the “Company”) is pleased to announce the presentation of updated data from its TACTI-mel Phase I clinical [...]

Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

23/03/2018 - 00:31

EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate siponimod also had beneficial [...]

CV Sciences, Inc. to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 29, 2018

23/03/2018 - 00:00

LAS VEGAS, March 22, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. , (OTCQB:CVSI) preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, today announced that it is scheduled to host a [...]

AFA: How Federal Spending Deal Impacts Individuals with Alzheimer’s

22/03/2018 - 23:04

NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- Boost to NIA/NIH Funding The omnibus federal spending deal, currently being considered by Congress, will deliver a $414 million funding increase for Alzheimer’s disease [...]

Vistin Pharma ASA : Key information for the subsequent repair issue

22/03/2018 - 22:47

Reference is made to the stock exchange notice from Vistin Pharma ASA earlier today, 22 March 2018, regarding a subsequent repair issue of approximately NOK 50 million. Key information for the subsequent repair issue is [...]

Vistin Pharma ASA : SUCCESSFULLY COMPLETED PRIVATE PLACEMENT

22/03/2018 - 22:29

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR [...]

Tergus Pharma announces the Acquisition of EnDev Labs

22/03/2018 - 22:10

RESEARCH TRIANGLE PARK, N.C., March 22, 2018 (GLOBE NEWSWIRE) -- Tergus Pharma, LLC, the leading global provider of dermatology Contract Research Organization (CRO) Services, today announced that it has acquired EnDev [...]

Healthcare Special Opportunities Fund Announces NAV Correction

22/03/2018 - 22:00

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, March 22, 2018 (GLOBE NEWSWIRE) -- (TSX:MDS.UN) – LDIC Inc. (the “ Manager ”), the manager of the Healthcare Special [...]

iKang Announces Unaudited Financial Results for the Fiscal Third Quarter Ended December 31, 2017

22/03/2018 - 22:00

BEIJING, March 22, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG ), major provider in China’s fast growing private preventive healthcare services market, today announced [...]

Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore

22/03/2018 - 21:35

MENLO PARK, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB ), the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S [...]